Publications by authors named "E Tsakni"
Article Synopsis
- TAF was found to be just as effective as TDF in suppressing hepatitis B virus (HBV) but had less impact on kidney health.
- This study compared post-liver transplant patients who switched from TDF to TAF due to low kidney function against those who remained on TDF, revealing no significant differences in renal function over a year.
- While no adverse effects from TAF were reported, and it showed a slight numerical improvement in kidney function, the overall conclusion was that switching to TAF did not significantly help kidney health for patients with chronic kidney disease (CKD) after one year.
Hepatitis E virus (HEV) is a well-known cause of acute hepatitis. Immunocompromised subjects, including liver transplant recipients, are considered to be at risk for HEV infection, which occasionally follows a chronic course. The diagnosis of HEV infection in these patients must be based on HEV RNA testing, as serology has variable performance.
View Article and Find Full Text PDFBackground: Nucleos(t)ide analogues (NAs) constitute the backbone of treatment for the prevention of hepatitis B virus recurrence after liver transplantation (LT). Decline in serum phosphorus levels is a common side effect of nucleotide therapy. Our aim was to assess the impact of nucleotide treatment on the occurrence of hypophosphatemia after LT and determine possible predictors.
View Article and Find Full Text PDFBackground: Diabetic nephropathy is the primary cause of end-stage renal disease (ESRD), which involves substantial economic burden. The primary objective of this study was to estimate the potential effect of losartan on the costs associated with ESRD in patients with diabetic nephropathy in a Greek setting. A secondary aim was to approximate the direct health care cost of renal replacement therapy (RRT) in Greece.
View Article and Find Full Text PDF